Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ready, Set, Lowest: Who Won China’s Latest Drug Bidding War?

Executive Summary

Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector. 

You may also be interested in...



Dr Reddy’s Pressing On In Russia, China Approvals Add Spark

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

Dr Reddy’s Pressing On In Russia, China Approvals Add Spark

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

India Pharma 2020: Trends That Can Change Business Tempo

Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel